Botulinum Toxin Type A — Safety Information

About this page: This is the complete safety reference for all botulinum toxin Type A products distributed by MJS Medicals. It applies to the full product catalog — Allergan Botox, Bienox, Botulax (100/200/300U), Dysport, Hitox, Hutox, INIBO, Innotox (50/100U liquid), Kaimax, Liztox, Meditoxin, Metox, Nabota (100/200U), Newlux, Onetox, ReNTOX, Redtox, Toxta, Vellux, WonderTox, Xeomin Korean Version, and Zerotox. Each product page links here rather than repeating the same safety content. Always refer to the manufacturer’s official prescribing information (Instructions for Use) before administration.

Last reviewed: May 2026 · Source verification: manufacturer official documentation cross-checked across multiple authorized distributors and regulatory databases.

Intended Users & Scope of Use

Botulinum toxin Type A is a prescription medical product. Administration is restricted to licensed healthcare professionals operating within their scope of practice — physicians, dermatologists, plastic surgeons, registered nurses (under supervision per local regulations), and trained aesthetic practitioners with documented botulinum toxin training. The practitioner is responsible for patient screening, dose calculation, aseptic reconstitution (where applicable), injection technique, and post-treatment patient guidance.

Botulinum toxin is not for personal use, self-injection, administration by non-medical personnel, or sale to retail consumers. Products are distributed exclusively for clinical and aesthetic medical use.

Contraindications (Absolute & Relative)

Do not administer botulinum toxin Type A to patients with the following:

• Neuromuscular junction disorders — myasthenia gravis, Lambert-Eaton myasthenic syndrome, amyotrophic lateral sclerosis (ALS), motor neurone disease
• Known hypersensitivity to botulinum toxin or any product excipient (human serum albumin, sodium chloride, lactose, sucrose, polysorbate 20, methionine, etc.)
• Cow’s milk protein allergy — specific contraindication for Dysport (contains 2.5 mg lactose excipient). Other botulinum products without lactose are generally not affected.
• Pregnancy or breastfeeding — insufficient safety data; the toxin’s potential for placental transfer or excretion in breast milk is not fully characterized
• Active local infection — inflammation, cellulitis, dermatitis, herpes outbreak, or any open wound at or near the planned injection site
• Drug interactions — aminoglycoside antibiotics (gentamicin, tobramycin, amikacin), anticholinesterase agents, curare-like neuromuscular blocking agents, magnesium sulfate (which may potentiate neuromuscular blockade)
• Bleeding disorders or anticoagulant therapy — heparin, warfarin, DOACs (apixaban, rivaroxaban), high-dose aspirin — relative contraindication due to elevated bruising risk
• Patients under 18 years for cosmetic indications (under 19 in Korea per local labels). Pediatric therapeutic indications require specialist supervision.
• History of dysphagia, aspiration, or respiratory compromise — increased risk of clinically significant systemic effects

Each product has specific contraindications detailed in the manufacturer’s official IFU — always review the IFU for the exact product before administration.

Possible Side Effects

Common reactions (mild, self-resolving within 1–7 days; typically local to the injection site):

• Pain, bruising, redness, swelling, or pinpoint bleeding at injection sites
• Headache (~1–2%)
• Temporary ptosis (eyelid drooping, ~2–3% for upper face injections)
• Brow asymmetry, eyebrow heaviness, or unintended facial expression changes
• Dry eye or excessive tearing (periocular treatments)
• Localized injection-site reactions (~4–5%)
• Mild, temporary muscle weakness in the treated area

Rare but serious — seek immediate medical attention:

• Difficulty breathing, swallowing (dysphagia), or speaking (dysphonia, dysarthria)
• Generalized muscle weakness or fatigue affecting body regions distant from the injection site
• Vision disturbance — blurred vision, diplopia, eyelid edema
• Urinary incontinence or retention
• Allergic reactions — urticaria, angioedema, anaphylaxis
• Persistent or worsening symptoms beyond 14 days post-injection

Drying Technology & Vial Appearance

Botulinum toxin Type A products in the MJS catalog use three different production technologies — and the resulting vial appearance differs significantly. Understanding this prevents fake-product complaints and reconstitution errors.

Why this matters: customers unfamiliar with vacuum-drying technology occasionally believe a Bienox or Nabota vial is empty and contact support. This is not a fake-product issue — it’s the normal appearance of vacuum-dried botulinum toxin. Conversely, if a freeze-dried product vial appears empty when it should contain visible powder, that is genuinely abnormal and warrants contacting us before use.

Korean-Imported Versions of Western Brands

Practitioners using these products should verify lot-level documentation against the manufacturer’s regional batch records if regulatory documentation is required for prescribing or insurance reimbursement.

Storage Requirements (All Botulinum Toxin Products)

• Continuous refrigeration at 2–8 °C from manufacturing through reconstitution (or use, for liquid Innotox)
• Do not freeze — freezing damages the protein structure and destroys potency. Repeated freeze/thaw cycles are not permissible.
• Do not expose to direct sunlight or heat
• Reconstitute powder products with sterile preservative-free 0.9% saline — gently swirl, do not shake (shaking can denature the protein)
• Innotox liquid format requires no reconstitution — withdraw directly from the vial with a sterile syringe
• Reconstituted shelf life: 24 hours at 2–8 °C for most products. Liztox is more conservative at 12 hours per Huons Biopharma official IFU.
• Unopened shelf life: typically 36 months from manufacturing date (verify each product’s label)

Dysport storage tolerance: unique to Dysport (Ipsen) — unopened vials tolerate a single exposure to temperatures up to 25 °C for up to 72 hours during shipping or temporary handling, after which they must return to 2–8 °C. This temperature excursion tolerance is broader than most other botulinum toxins.

Shipping & Cold Chain Tolerance

MJS Medicals ships all botulinum toxin products in insulated foam packaging with ice packs. Due to international shipping variables, ice packs may melt and packages may arrive at ambient temperature, particularly during warm seasons or in tropical destinations.

Brief room-temperature exposure during transit has minimal impact on lyophilized botulinum toxin potency. Published research indicates approximately 5–10% maximum potency reduction from short-duration ambient exposure. The lyophilized (freeze-dried or vacuum-dried) form is significantly more stable than reconstituted solution.

What to do upon arrival:

1. Refrigerate immediately at 2–8 °C
2. Inspect the vial — seal should be intact
3. For freeze-dried products (Botulax, Liztox, Hutox, Meditoxin, and most others), confirm visible white powder deposit at the bottom
4. For vacuum-dried products (Bienox, Nabota 100/200), do not be alarmed if the vial appears empty — hold up to light to see the thin film
5. For Innotox liquid, confirm visible clear liquid contents (not powder)
6. If the vial appears damaged, the seal is broken, or freeze-dried powder appears discolored, contact us before use

Reconstitution Standards

Powder botulinum products are reconstituted with sterile preservative-free 0.9% saline. Standard dilutions (per most manufacturer IFUs):

• Gentle swirl only — do not shake. Vigorous shaking creates foam and can denature the toxin protein, reducing potency.
• Reconstituted solution should be clear and colorless. Discard if turbid, discolored, or contains particulate matter.
• Use reconstituted solution within 24 hours (or 12 hours for Liztox) kept refrigerated at 2–8 °C.
• Innotox liquid format requires no reconstitution — withdraw directly with a sterile syringe.

Patient Aftercare Instructions

Practitioners should brief patients on the following post-treatment guidelines:

• 0–4 hours: Stay upright. Avoid lying flat, bending at the waist, or vigorous facial movement.
• 0–24 hours: Do not touch, press, or massage the treated area. Avoid alcohol consumption. Cold compresses may be applied gently for swelling.
• 0–48 hours: Avoid strenuous exercise, saunas, hot tubs, hot showers, and direct sun exposure.
• 0–2 weeks: No facial treatments such as laser, chemical peels, microneedling, dermabrasion, or aggressive facials.
• Always: Contact the treating practitioner immediately if any new breathing, swallowing, speaking, or vision difficulties appear.

Aftercare advice may vary slightly by treatment area and practitioner protocol. Patients should follow specific guidance from their treating professional.

Regulatory Status — Verifiable Approvals

MJS Medicals carries a mix of Korean-manufactured and Western-manufactured (Korean-imported) botulinum toxin products. Regulatory claims on this page are limited to those that can be verified in public regulatory databases or manufacturer documentation — we do not claim individual SKU-level approvals where verification is not available.

FDA-approved products on MJS (5 brands, 7 SKUs) — verifiable in FDA database:

• Botulax 100U / 200U / 300U (Hugel) — US FDA approved February 2024, marketed in the US as Letybo; Korean MFDS approval No. 3-48905.
• Nabota 100U / 200U (Daewoong) — US FDA approved February 2019, marketed in the US as Jeuveau; manufactured in Korea by Daewoong under K-GMP standards.
• Allergan Botox 50U Korean Version — original US FDA approval since 2002 (AbbVie/Allergan, manufactured in Ireland).
• Dysport 500U Korean Import — US FDA approved (Ipsen, distributed in the US by Galderma); CE marked in EU; manufactured in France/UK.
• Xeomin 100U Korean Version — US FDA approved (Merz, manufactured in Germany); EMA approved.

KFDA-approved Korean botulinum products (25 SKUs):

The remaining 25 SKUs are Korean-manufactured botulinum toxin products produced by major Korean pharmaceutical companies operating under K-GMP-certified facilities. These products include Bienox (BNC Korea), Hitox (Humedix), Hutox (Huons Global), INIBO, Innotox (Medytox, liquid), Kaimax (JETEMA), Liztox (Huons Biopharma, also CE-marked in select markets), Meditoxin (Medytox), Metox, Newlux, Onetox (JDBIO), ReNTOX (Pharma Research Bio, ISO 13485), Redtox, Toxta (JETEMA), Vellux (AEGEN Bio), WonderTox (Chong Kun Dang Pharmaceutical), and Zerotox (Hugel OEM). Most hold Korean Ministry of Food and Drug Safety (MFDS, formerly KFDA) approval; buyers should verify SKU-specific regulatory documentation with MJS customer service for jurisdictions requiring formal import compliance.

About MFDS specific registration numbers: MJS does not list individual SKU-level MFDS registration numbers on this page unless independently verifiable (Botulax: No. 3-48905). Buyers requiring SKU-specific MFDS documentation should request lot-level certificates from MJS customer service.

All Korean-only products are not currently FDA-approved in the United States. Buyers in the US, EU, and other regulated markets must verify their jurisdiction’s import regulations before purchase, importation, or administration. Regulatory status changes over time — verify current status with the appropriate regulatory authority.

Product Reference Table

Quick reference of the 32 SKUs in the MJS catalog by manufacturer, vial form (clinically relevant for reconstitution and visual inspection), and verifiable regulatory documentation. All Korean-manufactured products carry MFDS licensure by definition; the Approvals column shows only additional, publicly verifiable certifications, specific MFDS approval numbers, and international regulator approvals.

Vacuum-dried products: Powder forms an ultra-thin, almost invisible film at the bottom of the vial. Sealed vials may genuinely look empty on first inspection — this is the signature of vacuum-drying technology, not a packaging defect. Hold up to bright light at an angle to see the faint translucent film. Verify product authenticity before reconstitution.

Freeze-dried products (Botulax, Hutox, Liztox, Meditoxin, ReNTOX): Powder forms a visible white cake or granular deposit at the bottom of the vial, clearly visible to the naked eye. If you cannot see a powder deposit in a freeze-dried product vial, do not use it — contact us.

“—” in the Approvals column indicates this distributor has not independently documented additional certifications beyond MFDS licensure (which is required for all Korean-manufactured prescription products sold in Korea). Absence does not imply non-existence of approvals — manufacturers may hold additional certifications not publicly documented through our verification sources. Always refer to manufacturer official prescribing information for jurisdiction-specific authorization.